openPR Logo
Press release

Vernal Keratoconjunctivitis Pipeline Insight Market Research Report 2020 | Industry Overview by Therapy, Product Type, Emerging Drugs, Therapeutic Assessment, Phases, Pipeline Development & Major Manufactures Analysis

09-20-2020 11:27 AM CET | Health & Medicine

Press release from: Mart Research

/ PR Agency: Mart Research
Vernal Keratoconjunctivitis Pipeline Insight Market Research Report

Vernal Keratoconjunctivitis Pipeline Insight Market Research Report

Vernal Keratoconjunctivitis Pipeline Insight, 2020, report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
- Global coverage

Vernal Keratoconjunctivitis Understanding
Vernal Keratoconjunctivitis: Overview
Vernal Keratoconjunctivitis is a severe inflammatory disease that appears in children and adolescents with seasonal recurrence. It is most often seen in boys and tends to resolve at puberty. It is a relatively rare, chronic form of ocular allergy that can cause severe visual complications. Clinically, Vernal Keratoconjunctivitis can be divided into 3 subtypes: conjunctival, limbal, and mixed presentations.

Symptoms
Disease severity seems milder in limbal Vernal Keratoconjunctivitis, leading some to suspect that it is the early presentation of a spectrum of disease. However, there appears to be variability in the prevalence of certain types, based on geography and atopic history, which suggests that the pathogenesis of the two types may be different. The most common symptoms are itching, photophobia, burning, and tearing. The most common signs are giant papillae, superficial keratitis, and conjunctival hyperaemia.

Diagnosis
Differential diagnosis of Vernal Keratoconjunctivitis includes any of the chronic allergic conjunctivitis’s including seasonal allergic conjunctivitis, perennial allergic conjunctivitis, atopic keratoconjunctivitis, or giant papillary conjunctivitis, as well as chlamydial infection, especially in the early stages on the disease. Vernal Keratoconjunctivitis may be differentiated from the above disorders by hypertrophic papillae in the tarsal form of Vernal Keratoconjunctivitis or Horner Trantas dots in the limbal form, or a combination of the two, along with no involvement of the eyelids.

Request a Sample of Vernal Keratoconjunctivitis Pipeline Insight Market Research Report @ https://martresearch.com/contact/request-sample/2/46020

Treatment
There is currently no defined gold-standard treatment algorithm for Vernal Keratoconjunctivitis, but there are many options available, and treatment should be tailored to the individual. Whatever treatment regimen is prescribed, it should be initiated promptly and the patient should be monitored closely for the development of any corneal complications.
Therapies that are used for the treatment of Vernal Keratoconjunctivitis include:
- Mast cell stabilizers
- Antihistamines
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Topical corticosteroids
- Cyclosporine
- Tacrolimus
- Other therapies: Corticosteroids or other immunomodulatory agents

Vernal Keratoconjunctivitis Emerging Drugs Chapters
This segment of the Vernal Keratoconjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vernal Keratoconjunctivitis Emerging Drugs
- Lirentelimab (AK002): Allakos
Lirentelimab is an investigational, non-fucosylated IgG1 monoclonal antibody targeting Siglec-8. By targeting Siglec-8, an inhibitory receptor, lirentelimab blocks multiple inflammatory pathways. In clinical and preclinical studies, binding of lirentelimab to Siglec-8 induces inhibition of mast cells, apoptosis of tissue eosinophils, and depletion of blood eosinophils by antibody dependent cellular cytotoxicity (ADCC). Lirentelimab is being developed in several mast cell and eosinophil driven diseases, and has demonstrated positive clinical activity in eosinophilic gastrointestinal diseases (EGIDs), chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.

Further product details are provided in the report....

Browse the Full Vernal Keratoconjunctivitis Pipeline Insight Market Research Report @ https://martresearch.com/market-analysis/vernal-keratoconjunctivitis-pipeline-insight-2020/2/46020

Vernal Keratoconjunctivitis: Therapeutic Assessment
This segment of the report provides insights about the different Vernal Keratoconjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Vernal Keratoconjunctivitis
There are approx. 5+ key companies which are developing the therapies for Vernal Keratoconjunctivitis. The companies which have their Vernal Keratoconjunctivitis drug candidates in the early stage, i.e. phase I include, Allakos etc.

Phases
This report covers around 5+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

- Route of Administration
Vernal Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular

- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Monoclonal antibodies

- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vernal Keratoconjunctivitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vernal Keratoconjunctivitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vernal Keratoconjunctivitis drugs.

Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vernal Keratoconjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Vernal Keratoconjunctivitis.
- July 2020: Extension study shows efficacy of cyclosporine in treatment of vernal keratoconjunctivitis.
- An 8-month follow-up extension of the Vernal Keratoconjunctivitis Study, or VEKTIS, showed that continuous use of cyclosporine is safe and effective for the treatment of vernal keratoconjunctivitis in children and adolescents.
- The VEKTIS study was originally a 4-month evaluation of the safety and efficacy of cyclosporine A cationic emulsion (CsA CE) 0.1% eye drops administered four times daily (high dose) or twice daily (low dose) vs. vehicle only. One hundred sixty-nine patients between the ages of 4 and 17 years were included.

Vernal Keratoconjunctivitis Report Insights
- Vernal Keratoconjunctivitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs

Vernal Keratoconjunctivitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vernal Keratoconjunctivitis drugs?
- How many Vernal Keratoconjunctivitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vernal Keratoconjunctivitis?
- What are the key collaborations (Industry�Industry, Industry�Academia), Mergers and acquisitions, licensing activities related to the Vernal Keratoconjunctivitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vernal Keratoconjunctivitis and their status?
- What are the key designations that have been granted to the emerging drugs?

Key Players
- Santen SAS
- Allakos, Inc.
- Astellas Pharma Inc.
- Laboratoires Thea

Key Products
- NOVA22007
- AK002
- Cyclosporine
- FK506

Buy Full Vernal Keratoconjunctivitis Pipeline Insight Market Research Report @ https://martresearch.com/paymentform/2/46020/Single_User

Contact Us:
Mart Research
5708 Copper Creek Court Charlotte North Carolina 28227, USA
+1-857-300-1122
sales@martresearch.com

About Us:
We, at MART RESEARCH value your time the most as we believe that time saved is directly proportional to profits earned. Before launching ourselves into this service, we did an extensive survey to understand the challenges clients face while gaining access to authentic data reports. The need of the hour was a common platform which could showcase published reports across a wide range of sectors. To overcome this limitation, we setup a repository which is a comprehensive one-stop shop for all your report requirements. It is user friendly, easy to browse, search and acquire reports which would fulfill your generalized as well as customized business needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Vernal Keratoconjunctivitis Pipeline Insight Market Research Report 2020 | Industry Overview by Therapy, Product Type, Emerging Drugs, Therapeutic Assessment, Phases, Pipeline Development & Major Manufactures Analysis here

News-ID: 2137711 • Views: 363

More Releases from Mart Research

Deep Brain Stimulation Devices Pipeline Insight Market Research Report 2020 | Ad …
Deep Brain Stimulation Devices - Pipeline Insight and Competitive Landscape, 2020 report provides comprehensive insights about 20+ companies and 23+ pipeline devices in deep brain stimulation (DBS) devices pipeline landscape. The DBS market is expected to undergo substantial growth in the coming years owning to an increasing prevalence of neurological disorders around the world. The growing aging population is also a major growth factor for DBS devices market as
Artificial Lung Devices Pipeline Insight Market Research Report 2020 | ALung Tec …
Artificial Lung Devices - Pipeline Insight and Competitive Landscape, 2020 report provides comprehensive insights about 20+ companies and 23+ pipeline devices in artificial lung devices pipeline landscape. Globally, number of cases related to respiratory failure and cardiopulmonary collapse has grown rapidly. This has resulted in increasing demand for artificial lung that acts as an external support system providing oxygenation of blood and removal of carbon dioxide from the blood. Researcher
Biopsy Devices Pipeline Insight Market Research Report 2020 | Outlook, Product T …
Biopsy Devices - Pipeline Insight and Competitive Landscape, 2020 report provides comprehensive insights about 20+ companies and 23+ pipeline devices in biopsy devices pipeline landscape. Significant increase in incidence of cancer, such as breast, prostate, and lung, and rapid technological advancements such as 3D optical biopsies, MRI-targeted biopsies, and Ultrasound-guided biopsies fuel the adoption of biopsy devices. Moreover, rise in awareness on diagnosis of chronic diseases fosters the demand for
Coronary Stents Pipeline Insight Market Research Report 2020 | REVA Medical, Ron …
Coronary Stents - Pipeline Insight and Competitive Landscape, 2020 report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Coronary Stents pipeline landscape. Owing to the rise in the prevalence of coronary artery diseases (CAD), the coronary stents market is witnessing remarkable growth. Significant players are focusing on expanding their geographical reach, for dominating the current market. According to the Centre for Disease Control and Prevention, about one-third

All 5 Releases


More Releases for Vernal

Allergic Conjunctivitis Market - Patients, Treated Patients, by Countries, Disea …
Allergic conjunctivitis is a kind of eye disease in which it affect the eye surfaces and are commonly associated to immune-mediated inflammatory reactions of these structures. The prevalence of the allergic conjunctivitis is found more in summer and spring across the various regions. Pollen, dust, irritants such as cigarette smoke, perfumes etc. are some of the substance that triggers the conjunctivitis. Itching is the most typical sign of allergic conjunctivitis,
Global Eye Allergy (Allergic Conjunctivitis) Market: Treatment, Symptoms and Cau …
ResearchMoz incorporate new survey report "Global Allergic Conjunctivitis Market Size, Status and Forecast 2019-2025" to its immense accumulation of research reports. Allergic conjunctivitis is an eye inflammation caused by an allergic reaction to substances like pollen or mold spores. There are different types of allergic conjunctivitis such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant papillary conjunctivitis, vernal kerato conjunctivitis and atopic kerato conjunctivitis. In 2018, the global Allergic Conjunctivitis market size
Research delivers insight into the global Allergic Conjunctivitis market during …
Allergic conjunctivitis is an eye inflammation caused by an allergic reaction to substances like pollen or mold spores. There are different types of allergic conjunctivitis such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant papillary conjunctivitis, vernal kerato conjunctivitis and atopic kerato conjunctivitis. In 2017, the global Allergic Conjunctivitis market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR
Allergic Conjunctivitis Market 2025: Key Major Players are Santen Pharmaceutical …
ReportsnReports.com adds "Global Allergic Conjunctivitis Market, Patients, Treated Patients, by Countries (India, China, Japan, US, UK, etc), Disease Type (SAC, PAC, VKC, AKC, GPC), Drugs Profile (Zerviate, OTX-DP, ADX-102, PRT-2761, etc) Companies, Growth Drivers & Challenges" report to its research store. Access this Global Allergic Conjunctivitis Market report at https://www.reportsnreports.com/reports/1899647-global-allergic-conjunctivitis-market-patients-treated-patients-by-countries-india-china-japan-us-uk-etc-disease-type-sac-pac-vkc-akc-gpc-drugs-profile-zerviate-otx-dp-adx-102-prt-2761-etc-co-challenges.html. Allergic conjunctivitis is a kind of eye disease in which it affect the eye surfaces and are commonly associated to immune-mediated
Emerging Investment of Global Allergic Conjunctivitis Market to 2019-2025| Auven …
Researchmoz added Most up-to-date research on "Global Allergic Conjunctivitis Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. Allergic conjunctivitis is an eye inflammation caused by an allergic reaction to substances like pollen or mold spores. There are different types of allergic conjunctivitis such as seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant papillary conjunctivitis, vernal kerato conjunctivitis and atopic kerato conjunctivitis. To Get Sample Copy of Report visit @
Eye Allergy Treatment Poised To Attain High Growth With Top Industry Players: AL …
Market synopsis of global eye allergy treatment market: Market Scenario: Eye allergies are one of the most common health problems across the globe. Approximately 50 million people have some or the other kind of eye allergy in US alone. Some of the common eye allergy symptoms are redness, itching, and burning. Increasing prevalence of various eye allergies are key driver for the market while some other factors like increasing awareness, technological advancements, new